about
Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates.Coxiella burnetii infection in hemodialysis and other vascular grafts.Antifungal stewardship in daily practice and health economic implications.Clinical characteristics and predictors of mortality in cirrhotic patients with candidemia and intra-abdominal candidiasis: a multicenter study.Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation.The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin.No evidence of increased ocular involvement in candidemic patients initially treated with echinocandins.Association between source control and mortality in 258 patients with intra-abdominal candidiasis: a retrospective multi-centric analysis comparing intensive care versus surgical wards in Spain.A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality.Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels.Caspofungin versus fluconazole as prophylaxis of invasive fungal infection in high-risk liver transplantation recipients: A propensity score analysis.Combination of Candida biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment.Advances in the management of fungal infections.Are incidence and epidemiology of anaerobic bacteremia really changing?Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?Candidemia in non-ICU surgical wards: Comparison with medical wards.Is routine ophthalmoscopy really necessary in candidemic patients?Isavuconazole shortens the QTc interval.New antibiotics for ventilator-associated pneumonia.Dalbavancin in the treatment of different gram-positive infections: a real-life experience.Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review.Is Biofilm Production a Prognostic Marker in Adults with Candidemia?Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin.How to manage Pseudomonas aeruginosa infections.Repeated antifungal use audits are essential for selecting the targets for intervention in antifungal stewardshipRational approach in the management of P.aeruginosa infectionsT2 magnetic resonance for the diagnosis of deep-seated invasive candidiasis in a liver recipient without candidemiaDonor-derived invasive aspergillosis after kidney transplantFluconazole resistance is not a predictor of poor outcome in patients with cryptococcosisIncidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project.Challenges and research priorities to progress the impact of antimicrobial stewardshipThe role of new β-lactamase inhibitors in gram-negative infectionsDiagnosis and Treatment of Candidemia in the Intensive Care UnitRisk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteriaPersistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship eraManagement of patients with septic shock due to Candida infectionBloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter studyUsefulness of guideline recommendations for prognosis in patients with candidemia
P50
Q33773267-61568BE4-2E0F-471F-A422-38EC6B544B8CQ36150833-1A460E46-A0A9-4FA9-815C-90919D9EC182Q38511950-39ACEE4D-49E9-4FAD-8AC3-099C580A0A00Q40066371-CDDB08B2-9C31-4071-A4D9-F0011489BF4AQ40157393-ED7A7CF8-9337-4E04-AA1C-FB38D1874FB7Q40211933-5D47B279-316C-4CC1-A0F4-D08493E45E77Q40269000-B7C683C1-829D-4238-8825-48D670A36ACDQ40533714-EA0C73FD-3B00-4E72-9B62-AE13855C2E22Q40833322-6EE891B0-07C9-45BA-B1E7-B5EC88A2FB6FQ40842732-EA8B38A8-55CB-4475-A650-7BAC71D2671DQ40855547-A7C7562E-CEE7-4658-9979-E6D4307D99FCQ41031258-E39285D6-C7B6-4F65-9A45-E8F043C9F677Q41191253-F4107EE6-EF64-4064-A817-C0EC61AB3148Q41199404-A84625AD-AFD0-4196-99D8-49CF205849C3Q42209012-FAF28C40-3AD3-47E1-9048-27196546E488Q42680559-CD870380-993E-4CDF-8788-DAEEC5DEC10EQ44540929-494888C2-F65E-455D-8E41-C9A8FCFE6CB1Q47409728-908D46C7-347F-4FFC-8CF6-20F70639BCFBQ47655958-8C180ADF-3E5F-4F2E-924F-5EBCD6BDC539Q49588863-8BA0428D-F5D4-4F9C-A396-454652E3E024Q49604618-33D5AA41-D3E3-4C00-B866-48F49E19E934Q50165163-648DB0B5-539A-4E13-87A4-BBA76AB009A4Q52579373-38DFB38D-49DB-4FF4-8939-3E080A238E75Q54977074-C5A7DF09-DB8D-43EA-AD37-4C5C481095ECQ57137945-7D30EEC4-756C-4BDC-B7D4-7BF49A77C0B7Q57297336-223100C4-03FD-483E-9211-81E416A80499Q57826721-247772AE-B797-448E-A75B-1698F8EA65E7Q59354825-9DA9EAB0-3EE8-4BB0-A345-261836E1468DQ60860317-97B0EFC2-0915-4672-A5F7-D90D35AE7D9EQ64963259-E540B1C2-B5B1-4EDC-B713-BDBCF423E513Q90087449-36140F42-BED9-460B-8D0B-1EE6F6DCFD77Q90436627-F8391E4C-AC89-43E8-965E-A18B93F1B8E3Q90486856-8A90D72A-510F-4036-9824-AF9F42381454Q91196851-8324FF80-582F-431B-94EC-232FBFDD6F74Q91214777-0B8367C1-47D7-455C-8FA4-1C27DA33B081Q91250798-2A290FDA-9BC3-4B6D-AD3F-52E1C02EF9ABQ92405625-C445D0E7-7AAD-46CB-A5CB-B15A5935B01BQ93002833-69697DF6-75B5-4224-BEBE-E89B1138892F
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
A Vena
@en
A Vena
@nl
type
label
A Vena
@en
A Vena
@nl
prefLabel
A Vena
@en
A Vena
@nl
P31
P496
0000-0002-0697-3992